<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02146066</url>
  </required_header>
  <id_info>
    <org_study_id>0202EA</org_study_id>
    <nct_id>NCT02146066</nct_id>
  </id_info>
  <brief_title>Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221</brief_title>
  <acronym>DCVax-L EAP</acronym>
  <official_title>An Expanded Access Protocol for the Treatment of Glioblastoma Multiforme in Patients With Already Manufactured DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Who Have Screen-Failed Protocol 020221</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwest Biotherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwest Biotherapeutics</source>
  <brief_summary>
    <textblock>
      The study is an open-label expanded access study for patients for whom vaccine was
      manufactured during the Northwest Biotherapeutics' 020221 DCVax-L for GBM screening process,
      but who subsequently failed to meet specific enrollment criteria. Patients will receive
      therapy per investigator discretion (standard of care) as well as active vaccine per the
      020221 protocol administration schedule. It is estimated that approximately 99 patients will
      enroll in this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who are being screened under protocol 020221 who are not eligible for enrollment due
      to a) evidence of disease progression or pseudo-progression post chemo-radiation or b)
      insufficient (&lt;5 doses) vaccine manufactured, and for whom the DCVax-L treatment was
      manufactured and released are eligible for this study.

      Treatment Schedule:

      Open label vaccine injections will be give per the associated 020221 protocol. Injections
      will be given at days 0, 10, 20, and at months 2, 4, 8, 12, 18, 24 and 30. There are no
      therapeutic restrictions, but guidelines for drug administration are recommended as per the
      020221 protocol.

      Data collected includes vaccine administration information, and any vaccine related adverse
      event. Patient MRIs will be collected centrally for future review. Patients will be followed
      for disease progression and survival.
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>GBM</condition>
  <condition>Glioblastoma Multiforme</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DCVax-L</intervention_name>
    <description>Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Screen-Fail for protocol 020221 due to either:

               -  Radiographic evidence of disease progression or pseudoprogression at the Baseline
                  visit under protocol 020221, as determined by central imaging review, OR

               -  Insufficient vaccine manufactured for protocol 020221 (i.e. less than 5 doses).

          2. Patients must have a KPS rating of ≥70 at the Baseline Visit (Visit 5) (refer to
             Appendix D, Performance Status Scales).

          3. Patients may have received steroid therapy as part of their primary treatment. Steroid
             treatment should preferably be stopped; or if continued steroid use is clinically
             indicated, be tapered down to no more than 4 mg dexamethasone qd at least 7 days prior
             to the first immunization .

          4. DCVax-L product manufactured and released.

        Exclusion Criteria:

          1. Active uncontrolled infection, or acute infection requiring antibiotic or antifungal
             therapy. Antibiotic and antifungal therapy should be completed approximately 7 days
             prior to the first immunization.

          2. Fever ≥101.5oF. If considered possibly transient, retesting is allowed.

          3. Unstable or severe intercurrent medical conditions.

          4. Females of child-bearing potential who are pregnant or lactating or who are not using
             adequate contraception (abstinence, surgical, hormonal or double barrier, i.e. condom
             and diaphragm). 020221 Baseline lab results and or local lab results are acceptable.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Marnix Bosch, MBA PhD</last_name>
    <phone>240 497 9022</phone>
    <email>marnix@nwbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meghan Swardstrom</last_name>
    <phone>425 492 6036</phone>
    <email>mswardstrom@nwbio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Shana Fetters</last_name>
      <phone>501-686-8274</phone>
      <email>FettersShanaM@uams.edu</email>
    </contact>
    <investigator>
      <last_name>Shirley Ong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Diana Moughon</last_name>
      <phone>310-794-4223</phone>
      <email>dmoughon@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Linda Liau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Robin Bogardus</last_name>
      <phone>949-764-4624</phone>
      <phone_ext>57019</phone_ext>
      <email>alicia.bogardus@hoag.org</email>
    </contact>
    <investigator>
      <last_name>Christopher Duma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph Hospital of Orange</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Martha French</last_name>
      <phone>714-734-6200</phone>
      <phone_ext>40838</phone_ext>
      <email>Martha.French@stjoe.org</email>
    </contact>
    <investigator>
      <last_name>William Loudon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jinah Chung</last_name>
      <phone>714-456-8442</phone>
      <email>jinahec@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Daniela Bota, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Monica Robischon</last_name>
      <phone>720-848-0661</phone>
      <email>Monica.robischon@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin Lillehei, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Colorado Neurological Institute</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Alicia Novak</last_name>
      <phone>303-806-7423</phone>
      <email>anovak@thecni.org</email>
    </contact>
    <investigator>
      <last_name>Michael Pearlman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Whitney McNeal</last_name>
      <phone>352-273-7774</phone>
      <email>Whitney.McNeal@neurosurgery.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>David Tran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Healthcare System Memorial Cancer Institute</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Nithya Sundararaman, MA, MS, MBA, CCRP</last_name>
      <phone>+1-954-265-1846</phone>
      <email>NSundararaman@mhs.net</email>
    </contact>
    <contact_backup>
      <phone>(954) 265 1846</phone>
    </contact_backup>
    <investigator>
      <last_name>Atif Hussein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cadence Cancer Center at Warrenville</name>
      <address>
        <city>Warrenville</city>
        <state>Illinois</state>
        <zip>60555</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Claudia Fredian</last_name>
      <phone>630-352-5261</phone>
      <email>claudia.fredian@cadencehealth.org</email>
    </contact>
    <investigator>
      <last_name>Sean Grimm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Emma Breault</last_name>
      <phone>617-667-5984</phone>
      <email>ebreault@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>David Avigan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Marianne Morrissey</last_name>
      <phone>616-391-1129</phone>
      <email>marianne.morrissey@spectrumhealth.org</email>
    </contact>
    <investigator>
      <last_name>Wendy Sherman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Nasseff Neuroscience Institute - Abott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Anna Kistner</last_name>
      <phone>612-863-9166</phone>
      <email>Anna.Kistner@allina.com</email>
    </contact>
    <investigator>
      <last_name>John Trusheim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Hospital of Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jennifer McIntire</last_name>
      <phone>816-932-7985</phone>
      <email>jmcintire@saint-lukes.org</email>
    </contact>
    <investigator>
      <last_name>Darren Lovick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Andrew Wegrzyn</last_name>
      <phone>314-747-1825</phone>
      <email>awegrzyn@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Jian Campian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lori Cappello</last_name>
      <phone>201-996-5098</phone>
      <email>LCappello@HackensackUMC.org</email>
    </contact>
    <investigator>
      <last_name>Samuel Goldlust, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Capital Health</name>
      <address>
        <city>Trenton</city>
        <state>New Jersey</state>
        <zip>08638</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Cynthia Lewis-Diaz</last_name>
      <phone>609-394-6287</phone>
      <email>CDiaz@capitalhealth.org</email>
    </contact>
    <investigator>
      <last_name>Arlan Mintz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Louise Purcell</last_name>
      <phone>516-941-1263</phone>
      <email>lpurcell@nshs.edu</email>
    </contact>
    <contact_backup>
      <last_name>Michael Schulder, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center Neurological Institute of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Christina Corpus</last_name>
      <phone>212-342-1653</phone>
      <email>cc2638@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Fabio Iwamoto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Hospital</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Susan Fiore, M.S.</last_name>
      <phone>631-444-9425</phone>
      <email>susan.fiore@stonybrookmedicine.edu</email>
    </contact>
    <investigator>
      <last_name>Raphael Davis, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>043210</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Aubrey Hastings</last_name>
      <phone>614-293-8607</phone>
      <email>aubrey.hastings@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>J. Bradley Elder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Science Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Stephanie McKnight</last_name>
      <phone>405-271-8777</phone>
      <email>Stephanie-Mcknight@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>James Battiste, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lynne Belles</last_name>
      <phone>570-271-6780</phone>
      <email>lmbelles@geisinger.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Toms, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Suzanne Frangos, RN, CNRN</last_name>
      <phone>215-285-2885</phone>
      <email>suzanne.frangos@uphs.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Dept. of Neurosurgery</last_name>
      <phone>(215) 615-5436</phone>
      <email>Neurosurgery-NCRD@uphs.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Steven Brem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Thomas Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Nancy Grimes, RN</last_name>
      <phone>615-222-4356</phone>
      <email>ngrimes@sth.org</email>
    </contact>
    <investigator>
      <last_name>Steve Abram, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Neuroscience Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Nathan Hansen</last_name>
      <phone>206-320-3542</phone>
      <email>Nathan.Hansen@swedish.org</email>
    </contact>
    <investigator>
      <last_name>Charles Cobbs, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora Saint Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>23215</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lynda Yanny</last_name>
      <phone>414-649-6685</phone>
      <email>lynda.yanny@aurora.org</email>
    </contact>
    <investigator>
      <last_name>George Bobustuc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2014</study_first_submitted>
  <study_first_submitted_qc>May 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2014</study_first_posted>
  <last_update_submitted>February 25, 2016</last_update_submitted>
  <last_update_submitted_qc>February 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GBM</keyword>
  <keyword>Brain tumor</keyword>
  <keyword>glioblastoma</keyword>
  <keyword>Brain tumor WHO grade IV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

